Amgen Inc (AMGN) - Medical Equipment - Deals and Alliances Profile

Amgen Inc (AMGN) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME3778D
  • |
  • Pages: 106
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc (AMGN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Amgen Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Amgen Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 8

Amgen Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Amgen Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 10

Amgen Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 11

Amgen Inc, Medical Equipment, Deal Details 13

Venture Financing 13

Gamida Cell Raises USD 10 Million In Series E Financing 13

Partnerships 15

Biocartis Enters into Development Agreement with Amgen 15

Biocartis Enters into Co-Development Agreement with Amgen 16

Adaptive Biotechnologies Enters into Agreement with Amgen for Multiple Myeloma 17

Adaptive Biotech Enters into Agreement with Amgen 18

Biocartis Partners with Amgen 19

Exosome Diagnostics Enters into Agreement with Amgen 20

Flatiron Health Partners with Amgen 21

Biocartis Enters into Agreement with Amgen 22

Dako Enters into Co-Development Agreement with Amgen for Companion Diagnostic 23

Dako Enters Into Co-Development Agreement With Amgen For Molecular Diagnostic Test 24

Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 25

NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 26

KineMed Enters Into Co-Development Agreement With Amgen For Kinetic Biomarkers Of Brain Proteinopathies 27

Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 28

Dako Enters Into Co-Development Agreement With Amgen 29

Dako Enters Into Co-Development Agreement With Amgen 30

Merger 31

AstraZeneca Rumored To Merge With Amgen 31

Amgen Enters into Licensing Agreement with Unilife 32

Debt Offering 33

Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 33

Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 34

Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 35

Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 37

Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 38

Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 39

Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 40

Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 41

Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 42

Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 43

Unilife Raises USD30 Million in First Tranche of Private Placement of 6% Senior Secured Convertible Notes Due 2023 44

Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 46

Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 47

Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 48

Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 49

Amgen Raises USD850 Million in Public Offering of Notes Due 2017 50

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 52

Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 54

Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 56

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 58

Acquisition 60

Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For USD 401 Million 60

Amgen Inc-Key Competitors 62

Amgen Inc-Key Employees 63

Amgen Inc-Locations And Subsidiaries 65

Head Office 65

Other Locations & Subsidiaries 65

Joint Venture 70

Recent Developments 72

Strategy And Business Planning 72

Apr 10, 2018: Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant 72

Jun 02, 2017: Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge 73

Financial Announcements 74

Jul 26, 2018: Amgen reports second quarter 2018 Financial Results 74

Apr 24, 2018: Amgen Announces First Quarter 2018 Financial Results 77

Feb 01, 2018: Amgen Reports Fourth Quarter And Full Year 2017 Financial Results 79

Oct 25, 2017: Amgen Reports Third Quarter 2017 Financial Results 82

Jul 25, 2017: Amgen Reports Second Quarter 2017 Financial Results 84

Apr 26, 2017: Amgen Reports First Quarter 2017 Financial Results 86

Feb 02, 2017: Amgen Reports Fourth Quarter And Full Year 2016 Financial Results 89

Corporate Communications 92

Jul 26, 2018: Amgen Announces Succession Plans For Two Executive Officers 92

Dec 11, 2017: Amgen Foundation Pledges Up To USD 500,000 In Relief To Victims Of The Southern California Wildfires 93

Oct 24, 2017: Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors 94

Sep 22, 2017: Amgen Foundation Pledges Up To USD 5 Million To Hurricane Maria Relief Efforts 95

Feb 03, 2017: Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors 96

Government and Public Interest 97

Jul 11, 2017: Amgen And QB3@953 Announce Winners Of The Amgen Golden Ticket 97

Other Significant Developments 98

Sep 24, 2018: MedTech Innovator announces newest industry partners 98

Sep 20, 2018: Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub-BioLA 99

Sep 10, 2018: Amgen selects Deloitte to provide an integrated patient services platform 100

Mar 08, 2018: Amgen Announces Final Results Of Tender Offer 101

Mar 06, 2018: Amgen Announces Preliminary Results Of Tender Offer 102

Sep 25, 2017: Amgen Provides Update On Hurricane Maria 103

Mar 29, 2017: Amgen Enters into Agreement with Inovalon and Avalere to Engage Value-based Contracting Opportunities 104

Jan 09, 2017: DaVita Enters Into New Sourcing and Supply Agreement with Amgen and Initiates 2017 Kidney Care Guidance 105

Appendix 106

Methodology 106

About GlobalData 106

Contact Us 106

Disclaimer 106

List of Figures

Amgen Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Amgen Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Amgen Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Amgen Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Amgen Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Amgen Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 8

Amgen Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Amgen Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 10

List of Tables

Amgen Inc, Medical Equipment, Key Facts, 2017 2

Amgen Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Amgen Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 7

Amgen Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 8

Amgen Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 9

Amgen Inc, Deals By Market, 2012 to YTD 2018 10

Amgen Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 11

Gamida Cell Raises USD 10 Million In Series E Financing 13

Biocartis Enters into Development Agreement with Amgen 15

Biocartis Enters into Co-Development Agreement with Amgen 16

Adaptive Biotechnologies Enters into Agreement with Amgen for Multiple Myeloma 17

Adaptive Biotech Enters into Agreement with Amgen 18

Biocartis Partners with Amgen 19

Exosome Diagnostics Enters into Agreement with Amgen 20

Flatiron Health Partners with Amgen 21

Biocartis Enters into Agreement with Amgen 22

Dako Enters into Co-Development Agreement with Amgen for Companion Diagnostic 23

Dako Enters Into Co-Development Agreement With Amgen For Molecular Diagnostic Test 24

Illumina Enters Into Co-Development Agreement With Amgen For Oncology Companion Diagnostic Test 25

NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 26

KineMed Enters Into Co-Development Agreement With Amgen For Kinetic Biomarkers Of Brain Proteinopathies 27

Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 28

Dako Enters Into Co-Development Agreement With Amgen 29

Dako Enters Into Co-Development Agreement With Amgen 30

AstraZeneca Rumored To Merge With Amgen 31

Amgen Enters into Licensing Agreement with Unilife 32

Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 33

Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 34

Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 35

Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 37

Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 38

Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 39

Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 40

Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 41

Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 42

Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 43

Unilife Raises USD30 Million in First Tranche of Private Placement of 6% Senior Secured Convertible Notes Due 2023 44

Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 46

Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 47

Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 48

Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 49

Amgen Raises USD850 Million in Public Offering of Notes Due 2017 50

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 52

Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 54

Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 56

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 58

Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For USD 401 Million 60

Amgen Inc, Key Competitors 62

Amgen Inc, Key Employees 63

Amgen Inc, Other Locations 65

Amgen Inc, Subsidiaries 67

Amgen Inc, Joint Venture 70

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Amgen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18103
Site License
USD 500 INR 36205
Corporate User License
USD 750 INR 54308

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com